Axisgroup
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
US In-Vitro Diagnostics Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 72 pages | Đã xuất bản: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 72 pages
- Published: 10-06-2019
Market Overview
The key factors propelling the growth of the market is the high prevalence of chronic diseases, increasing use of POC (Point-of-care) diagnostics, advanced technologies, and increasing awareness and acceptance of personalized medicine. The increasing government healthcare expenditure and consumer’s healthcare spending are also responsible for the growth of the market.
The increase in the US in vitro diagnostics market is majorly due to the high prevalence of chronic diseases, such as heart diseases, cancer, asthma, and diabetes. It is estimated that these diseases are responsible for the majority of deaths in the United States, killing more than 1.7 million US citizens annually. Thus, IVDs have proved to be beneficial in managing these chronic conditions. IVDs help in the detection of early warning signs and individual risk factors, creating new opportunities for prevention and early intervention.
There are also emerging technological innovations, such as lab-on-a-chip, wearable devices, and POC diagnostics that are increasingly becoming an important part of the healthcare landscape. These POC diagnostic products have been developed to be used on a patient’s bedside in hospitals, to get instant results without the need of sending the samples to the lab. Thus, owing to the ease of use and the ability to provide instant results, the use of POC diagnostics in the United States is increasing rapidly.
Scope of the Report
As per the scope of the report, in vitro diagnostics are the medical devices and consumables utilized to perform in vitro tests on various biological samples. They are basically used for the diagnosis of various medical conditions. These in vitro diagnostics products can be instruments, reagents, or any system used for the diagnosis of diseases.
Key Market Trends
Cancer/Oncology is the Segment by Application that is Expected to Grow the Fastest During the Forecast Period
Oncology is expected to witness the fastest CAGR, due to the rising number of cancer cases in the United States. There is also an increasing demand for self-care devices and POC diagnostics in the United States for the treatment of chronic diseases that is expected to boost the market growth in the forthcoming years.
The infectious disease segment also holds the largest market share, due to a high prevalence of pneumonia, tuberculosis, and HIV/AIDS. Thus, with the increasing cases of infectious diseases, it is expected to contribute to the growth of the US in vitro diagnostics market.
Hospitals is the Largest Segment by End User that is Expected to Grow During the Forecast Period
Hospitals hold the largest market share, in terms of revenue, owing to the large volume of diagnostic tests carried out in hospitals and the rising volumes of Class II and Class III IVD medical devices that are being readily used for diagnostic testing. The healthcare professionals present in hospitals mostly utilize in vitro diagnostics for disease detection and to get the best results for each patient.
Competitive Landscape
Companies, like GE Healthcare, Becton Dickinson, and Quidel, are adopting strategic actions, mergers and acquisitions, and continued technological advancements, in order to retain their market share in the future. The companies are focusing on increasing technological advancements in order to address the customer needs, like fully automated systems that provide fast and accurate results.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics Spurring the IVD Market
4.2.3 Increasing Government Healthcare Expenditure and Consumer’s Healthcare Spending
4.2.4 Advanced Technologies Fueling the IVD Market
4.2.5 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Lack of Proper Reimbursement
4.3.2 Stringent Regulatory Framework
4.3.3 Need For High Complexity Testing Centers
4.4 Porters Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technique
5.1.1 Immunochemistry
5.1.2 POC Diagnostics
5.1.3 Molecular Diagnostics
5.1.4 Hematology
5.1.5 Tissue Diagnostics
5.1.6 Microbiology
5.1.7 Glucose Monitoring
5.1.8 Other Techniques
5.2 By Product
5.2.1 Instruments
5.2.2 Reagents
5.2.3 Data Management Systems
5.3 By Usability
5.3.1 Disposable IVD
5.3.2 Reusable IVD
5.4 By Application
5.4.1 Infectious Diseases
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Diseases
5.4.6 Nephrology
5.4.7 Drug Testing
5.4.8 HIV/AIDS
5.4.9 Other Applications
5.5 By End User
5.5.1 Laboratories
5.5.2 Hospitals
5.5.3 Academia
5.5.4 Other End Users
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Becton Dickinson & Company
6.1.4 Danaher Corporation
6.1.5 bioMerieux SA
6.1.6 Bio-Rad Laboratories, Inc.
6.1.7 Thermo Fisher Scientific Inc.
6.1.8 Qiagen
6.1.9 Siemens Healthcare GmBH
6.1.10 Sysmex Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technique
Immunochemistry
POC Diagnostics
Molecular Diagnostics
Hematology
Tissue Diagnostics
Microbiology
Glucose Monitoring
Other Techniques
By Product
Instruments
Reagents
Data Management Systems
By Usability
Disposable IVD
Reusable IVD
By Application
Infectious Diseases
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Diseases
Nephrology
Drug Testing
HIV/AIDS
Other Applications
By End User
Laboratories
Hospitals
Academia
Other End Users
Acute Myeloid Leukemia Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Đã xuất bản: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 10-06-2019
Market Overview
The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%. The key factors propelling the growth of this market are high Incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in R&D by the pharmaceutical companies.
The American Cancer Society’s estimates for leukemia in the United States, for 2019, indicates that approximately 61,780 new cases of leukemia and 22,840 deaths from leukemia are expected to occur in the country. Among them, the number of new cases of acute myeloid leukemia (AML) will be around 21,450, from which most of the population will be adults. In terms of mortality, the society has estimated that there will be around 10,920 deaths due to AML, in the country. This statistics shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impact the growth of the AML market in the United States.
In addition, the global rise in the incidence of AML, along with increased mortality due to the disease, is expected to create a huge demand for AML therapeutics, thus, augmenting the global AML market.
Scope of the Report
This report estimates the global acute myeloid leukemia market and includes a detailed analysis of cytarabine, anthracycline drugs, and daunomycin.
Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body against infections caused by bacteria.
Key Market Trends
Cytarabine is Expected to hold its Highest Market Share in the Chemotherapy Segment
In the chemotherapy segment of the acute myeloid leukemia market, cytarabine is believed to have the largest market size and is expected to witness a CAGR of 14.3% during the forecast period.
Most of the times, surgery and radiation therapy in cancer patients remove, kill, or damage cancer cells in a certain area, but chemotherapy works throughout the whole body and gives better results. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body. On the contrary, surgery and radiation only attack or kill the tumor that is located in a specific part. Since cancer is the disease which, most of the times, spreads across the whole body in a short period of time, oncologists choose to perform chemotherapy for better results.
Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin’s lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations. The American Cancer Society had estimated around 21,380 new cases of acute myeloid leukemia (AML) and approximately 10,590 deaths from AML in the United States, in 2016.
According to this society, these statistics involve a large percentage of the adult population. The increasing number of AML patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of AML in the country is the prime factor responsible for the growth of the market in the country.
Competitive Landscape
The acute myeloid leukemia market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new techniques with good results. Companies, like Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, and Sanofi-Aventis (Genzyme Corporation), hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
4.2.3 Increasing Investments in R&D
4.3 Market Restraints
4.3.1 Stringent Regulations on Drugs
4.3.2 Complications Related to Chemotherapy
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Chemotherapy
5.1.1 Cytarabine
5.1.2 Anthracycline Drugs
5.1.2.1 Daunomycin
5.1.2.2 Idarubicin
5.1.2.3 Mitoxantrone
5.1.3 Alkylating Agents
5.1.4 Anti-metabolites
5.1.5 Tyrosine Kinase Inhibitors
5.1.5.1 Dasatinib (Sprycel)
5.1.5.2 Imatinib (Gleevec)
5.1.6 Hormonal Therapy
5.1.7 Other Chemotherapies
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Celegene Corporation
6.1.2 Novartis AG
6.1.3 Genmab AS
6.1.4 Eisai Co. Ltd
6.1.5 Sanofi-Aventis (Genzyme Corporation)
6.1.6 Teva Pharmaceutical (Cephalon Inc.)
6.1.7 Pfizer Inc.
6.1.8 Bristol-Myers Squibb Company
6.1.9 Sunesis Pharmaceuticals Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Chemotherapy
Cytarabine
Anthracycline Drugs
Daunomycin
Idarubicin
Mitoxantrone
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Dasatinib (Sprycel)
Imatinib (Gleevec)
Hormonal Therapy
Other Chemotherapies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Human Microbiome Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Đã xuất bản: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 10-06-2019
Market Overview
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
Scope of the Report
The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.
Key Market Trends
Therapeutic Applications is Expected to hold the Highest Market Share
The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.
Competitive Landscape
The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Therapeutics
5.1.2 Diagnostics
5.2 Disease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Therapeutics
Diagnostics
Disease
Obesity
Diabetes
Autoimmune Disorder
Cancer
Gastrointestinal Disorders
Central Nervous System Disorders
Other Diseases
Product
Probiotics
Prebiotics
Symboitics
Other Products
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Market Overview
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
Scope of the Report
The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.
Key Market Trends
Therapeutic Applications is Expected to hold the Highest Market Share
The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.
Competitive Landscape
The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Therapeutics
5.1.2 Diagnostics
5.2 Disease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Therapeutics
Diagnostics
isease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Alzheimer’s Disease Diagnostics and Therapeutics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Đã xuất bản: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The global Alzheimer’s disease diagnostics and therapeutics market was valued at USD 7,537.4 million in 2018, and is estimated to be valued at USD 11,138.2 million in 2024, witnessing a CAGR of 6.7%. The key factors propelling the growth of this market are investment in biomarkers for drug development, increasing pipeline drug development, increasing sophisticated diagnostics for early detection, along with more precise drug development, and emerging novel diagnostics technologies.
Alzheimer’s disease is one of the most prevalent types of dementia that occurs worldwide. According to the Alzheimer’s disease facts and figures, it is estimated that in every 33 seconds, a new case of Alzheimer’s disease occurs, leading to high prevalence of the disease, of almost 35 million patients, around the world. The development of clinical diagnostics and therapeutics for Alzheimer’s disease (AD) and other neurodegenerative conditions is becoming very important. In about 10-15% cases, the clinical diagnosis of AD is inaccurate. So, certain biomarkers that may improve the accuracy of the diagnosis are used. Biomarkers are neurochemical indicators used to determine the risk or prevalence of the disease.
Investing in biomarkers for drug development and early detection of AD acts as a major driver, and fuels the growth of the Alzheimer’s disease diagnostics and therapeutics market, globally.
Scope of the Report
As per the scope of the report, Alzheimer’s disease (AD) is a progressive, degenerative disorder that attacks the brain’s nerve cells or neurons, resulting in loss of memory, thinking and language skills, and behavioural changes.
Key Market Trends
Cholinesterase Inhibitors are Expected to hold the Highest Market Share in the Therapeutics Segment
In the therapeutics segment of the Alzheimer’s disease diagnostics and therapeutics market. Cholinesterase inhibitors are believed to have the largest market size and are expected to witness a CAGR of 6.4% during the forecast period.
Cholinesterase inhibitors are used for the treatment of Alzheimer’s. These cholinesterase inhibitors are approved by the US FDA. Most physicians and perhaps most patients consider cholinergic drugs. Donepezil, galantamine, and rivastigmine are the generic names of cholinesterase inhibitors, which are likely to be the first-line pharmacotherapy choice for mild to moderate Alzheimer’s disease. These drugs have somewhat different pharmacological properties, but all of them work by the same mechanism, which involves inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.
The market is dominated by leading brands, such as Aricept, Exelon, and Reminyl; Aricept, whose active ingredient is a cholinesterase inhibitor, holds the largest market share. Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Hence, oeing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for Alzheimer’s disease diagnostics and therapeutics ,and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer’s disease diagnostics and therapeutics market. According to the Alzheimer’s Association, more than 5 million Americans suffer from Alzheimer’s, as of 2017. The United States is considered to be the global leader in Alzheimer’s disease intervention and management. America has a large pool of biopharmaceutical companies, which cumulatively have 85 drugs for combating Alzheimer’s disease in various stages of the pipeline. Hence, the market is expected to register a healthy CAGR over the forecast period.
Competitive Landscape
The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are increasing their market presence, by introducing new technologies with better results. Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., hold a substantial market share in the Alzheimer’s disease diagnostics and therapeutics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Investment in Biomarkers for Drug Development
4.2.2 Increasing Pipeline Drug Development
4.2.3 Increasing Sophisticated Diagnostics for Early Detection and More Precise Drug Development
4.2.4 Emerging Novel Diagnostic Technologies
4.3 Market Restraints
4.3.1 Early Diagnosis of the Indication is Challenging
4.3.2 Decline in the Market Due to Failures of Late-stage Drugs
4.3.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
4.3.4 Insufficient Research Funding and Lengthy, Expensive, and Uncertain Process
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Therapeutics
5.1.1 Cholinesterase Inhibitors
5.1.2 NMDA Receptor Antagonists
5.1.3 Other Therapeutics
5.2 By Diagnostics
5.2.1 Brain Imaging
5.2.2 CFS Test for Alzheimer’s Disease
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche
6.1.2 Novartis AG
6.1.3 Merck & Co. Inc
6.1.4 Pfizer Inc
6.1.5 Eisai Co. Ltd
6.1.6 Biogen Inc
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly & Company
6.1.9 Amarantus Bioscience Holdings Inc
6.1.10 Diagenic ASA
6.1.11 Navidea Biopharmaceuticals
6.1.12 GE Healthcare
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Therapeutics
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Other Therapeutics
By Diagnostics
Brain Imaging
CFS Test for Alzheimer’s Disease
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Neurology Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Đã xuất bản: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the market are the increasing incidence of neurological disorders, huge investments by private players in neurology devices, increase in R&D in the field of neurotherapies, and rising aging population.
The growth of the global neurology devices market is attributed to the increasing incidence of neurological disorders that include brain aneurysms, brain tumors, epilepsy, memory disorders, multiple sclerosis, Parkinson’s disease, peripheral neuropathy, post-herpetic neuralgia, spinal cord tumor, and stroke.
The increasing healthcare spending, increasing foreign direct investment by global medical device manufactures, and increasing neurological disease prevalence are expected to drive the overall market growth.
Scope of the Report
As per the scope of the report, neurological devices are medical devices that help to diagnose, prevent, and treat a variety of neurological disorders and conditions, such as Alzheimer’s disease, Parkinson’s disease, major depression, and traumatic brain injury. The growth of neurological devices is being driven through an emphasis on developing superior neuromodulation and neurostimulation techniques, leveraging minimally invasive procedures that benefit patients. This has resulted in companies investing more in R&D, in an effort to better treat and rehabilitate the brain.
Key Market Trends
Sacral Nerve Stimulation Devices is the Segment under Neurostimulation Devices that is Expected to Grow Fastest during the Forecast Period
The sacral nerve stimulation devices are mostly used for patients for whom drug therapy or other types of medications are not successful. It is performed with the help of a small device, which is capable of sending electrical impulses to the targeted sacral nerves located in the lower back region. These devices are found to be successful in treating bladder problems. Hence, with increasing incidences of overactive bladder, the sacral nerve stimulation devices segment is expected to grow during the forecast period.
The deep brain stimulation devices are also being used to perform deep brain stimulation procedures, by implanting a medical device that is capable of sending electrical impulses to specific target areas in the brain. These devices are generally used to treat neuropsychiatric disorders and are effectively used in treating various other neurological disorders, like Parkinson’s disease, essential tremor, dystonia, chronic pain, major depression, and obsessive-compulsive disorder.
Asia-Pacific Registered the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period
The Asia-Pacific region is expected to grow, due to the presence of high unmet medical needs, coupled with rapidly rising healthcare R&D investments and growing medical expenditures in emerging economies, such as India and China. There are also a number of government initiatives that are expected to increase over the forecast period.
Competitive Landscape
There are market participants involved in R&D for the development of advanced stimulation and neuromodulation techniques with minimally invasive procedures that are more preferable to the patients. Furthermore, many private companies are showing great interest in developing novel neurological devices to earn huge profits.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence of Neurological Disorders
4.2.2 Huge Investments by Private Players in Neurology Devices
4.2.3 Increase in R&D in the Field of Neurotherapies
4.2.4 Rise in the Aging Population
4.3 Market Restraints
4.3.1 High Cost of Equipment
4.3.2 Stringent FDA Validation and Guidelines for New Devices
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Device
5.1.1 Cerebrospinal Fluid Management Devices
5.1.2 Interventional Neurology Devices
5.1.2.1 Interventional/Surgical Simulators
5.1.2.2 Neurothrombectomy Devices
5.1.2.3 Carotid Artery Stents
5.1.2.4 Embolic Coils
5.1.2.5 Support Devices
5.1.3 Neurosurgery Devices
5.1.3.1 Neuroendoscopes
5.1.3.2 Stereotactic Systems
5.1.3.3 Aneurysm Clips
5.1.3.4 Other Neurosurgery Devices
5.1.4 Neurostimulation Devices
5.1.4.1 Spinal Cord Stimulation Devices
5.1.4.2 Deep Brain Stimulation Devices
5.1.4.3 Sacral Nerve Stimulation Devices
5.1.4.4 Other Neurostimulation Devices
5.1.5 Other Types of Devices
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 Boston Scientific Corporation
6.1.3 Stryker Corporation
6.1.4 Medtronic PLC
6.1.5 Abbott Laboratories
6.1.6 Johnson and Johnson
6.1.7 Smith & Nephew
6.1.8 MicroPort Scientific Corporation
6.1.9 Nihon Kohden Corporation
6.1.10 Penumbra Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type of Device
Cerebrospinal Fluid Management Devices
Interventional Neurology Devices
Interventional/Surgical Simulators
Neurothrombectomy Devices
Carotid Artery Stents
Embolic Coils
Support Devices
Neurosurgery Devices
Neuroendoscopes
Stereotactic Systems
Aneurysm Clips
Other Neurosurgery Devices
Neurostimulation Devices
Spinal Cord Stimulation Devices
Deep Brain Stimulation Devices
Sacral Nerve Stimulation Devices
Other Neurostimulation Devices
Other Types of Devices
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Whole Slide Imaging Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Đã xuất bản: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the whole slide imaging market are increasing usage in drug discovery processes, technological advancements in whole slide imaging, and rising popularity of virtual slides, as compared to physical slides. Also, the increasing incidence of cancer is expected to drive the growth of the overall market.
With increasing research, there are many pharmaceutical and biotech companies that have made significant investments in drug discovery. As a consequence, imaging is now performed in all drug discovery processes. Therefore, imaging and image-based technologies are now commonplace across the drug discovery workflow and hold great promise for R&D, allowing researchers to understand and work with model organisms. Thus, it is expected to improve standardization, quality, and manageability of research, and help reduce costs. Thus, as research in drug discovery increases, it is expected to directly impact the growth of the whole slide imaging market.
Digital pathology (DP) is also a rapidly growing field that has generated a lot of interest among hospitals, laboratories, surgeons, research institutes, and healthcare companies, among others. The digital pathology process is expected to significantly increase, and thereby, increase productivity and efficiency, by allowing pathologists to stay in their offices rather than travel to numerous locations.
With the advancement of digital pathology and computer-assisted artificial intelligence technology, it is inevitable that digital health will come to play an important role in the strategic planning of cancer research and precision medicine delivery.
Thus, whole slide imaging devices are increasingly being used for cancer research and precision medicine, as many diseases can be defined by being examined under the microscope. Pathologists’ involvement in precision medicine and digital technology is likely to be a key driver for improving patient care. As a result, this is a great opportunity for the growth of the market.
Scope of the Report
As per the scope of the report, whole slide imaging involves physical slides, which are transformed into digital resources that can be analyzed on any computer, easily stored, and quickly shared with colleagues wherever they are. It refers to the scanning of conventional glass slides, in order to produce digital slides, and is the most recent imaging modality being employed by pathology departments, worldwide.
Key Market Trends
Immunohistochemistry Application Segment is Expected to Grow the Fastest During the Forecast Period
Immunohistochemistry (IHC) is a method for detecting antigens or haptens in the cells of a tissue section, by using the principle of antibodies binding specifically to antigens in biological tissues. It is a widely used technique in pathology to observe protein expression in tissue samples. It is also gaining importance, as many biotech companies use immunohistochemistry in early research and later stage drug development. Thus, with more advanced processes, this method helps in faster assessment of samples.
There has also been increased use of whole slide imaging to study blood coagulation disorders to hematopoietic neoplasms. Although there has been increased interest by pharmaceutical companies to use WSI products to develop biomarkers, the acceptance of digitized images in clinical validation studies by regulatory authorities still remains a challenge.
The Asia-Pacific Market Holds the Fastest Growth, and is Expected to Follow the Same Trend over the Forecast Period
The Asia-Pacific market is witnessing the highest CAGR, owing to the same factors responsible for the growth of this market, such as increasing research on drug discovery and awareness about the benefits of WSI. The market for whole slide imaging is growing every year and generating a large number of pathology specimens each year, due to the presence of a large population base. Thus, the adoption rate of whole slide imaging in the region has also increased, and is expected to rise in the same manner over the coming years.
Competitive Landscape
In the last decade, many pharmaceutical and biotech companies made significant investments in imaging in drug discovery. There has also been increased interest by pharmaceutical companies to use WSI products to develop biomarkers, companion, or complementary diagnostics. Many manufacturing companies are, thus, looking for opportunities in different market economies, such as Europe and Canada, where the policies are not as stringent and are better integrated.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Popularity of Virtual Slides as Compared to Physical Slides
4.2.2 Technological Advancements in Whole Slide Imaging
4.2.3 Increasing Research in Drug Discovery
4.3 Market Restraints
4.3.1 Stringent Regulatory Approvals
4.3.2 High Cost of Whole Slide Imaging Systems
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Scanners
5.1.2 IT Infrastructure
5.1.3 Viewer
5.1.4 Image Management System
5.2 By Application
5.2.1 Telepathology
5.2.2 Cytopathology
5.2.3 Immunohistochemistry
5.2.4 Hematopathology
5.3 By End User
5.3.1 Education
5.3.2 Research
5.3.3 Clinical
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Olympus Corporation
6.1.2 Philips Healthcare
6.1.3 Definiens AG
6.1.4 Leica Microsystems GmbH
6.1.5 Ventana Medical Systems Inc.
6.1.6 Nikon Corporation
6.1.7 Visiopharm
6.1.8 3Dhistech
6.1.9 Hamamatsu Photonics KK
6.1.10 Indica Labs
6.1.11 Inspirata
6.1.12 Mikroscan Technologies Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Scanners
IT Infrastructure
Viewer
Image Management System
By Application
Telepathology
Cytopathology
Immunohistochemistry
Hematopathology
By End User
Education
Research
Clinical
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America